UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD

ACRUX DDS PTY LTD. & ACRUX LIMITED Petitioners,

V.

KAKEN PHARMACEUTICAL CO., LTD. and VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Patent Owner and Licensee.

Case: IPR2017-00190 U.S. Patent No. 7,214,506

PATENT OWNER'S RESPONSE



Table of Contents

I.	Intro	t roduction ϵ			
II.	Technical Background				
	A.	A. Onychomycosis is an Infection of the Nail Plate and Underlying Nail Bed			
	B.	Nail is Unlike Skin and Hair, Producing Distinct Interactions with Antifungal Agents	11		
	C.	Uncertainty in the Art Regarding the Factors Contributing to the Effectiveness of a Topical Treatment Hindered Development	13		
	D.	Many Antifungal Agents were Available Prior to the '506 Patent but Lacked Proven Efficacy in Treating Onychomycosis Topically	15		
III.	The Discovery of Efinaconazole was a Breakthrough for the Field				
	A.	The Claimed Invention and the '506 Patent	19		
	B.	Efinaconazole Displays Superior Efficacy	22		
IV.	Relev	vant Field and the Person of Ordinary Skill in the Art2			
V.	Clain	im Construction2			
VI.	Prior	ority Date			
VII.	The Challenged Claims are Not Obvious Over the Cited Art				
	A.	Overview of Nonobviousness Position	32		
	В.	Petitioner's Primary References Only Relate to the Use of Efinaconazole in Skin	35		
		The Kaken Abstracts Test Efinaconazole <i>In Vitro</i> and in a Guinea Pig Model of Skin Infection	35		
		Ogura Is Not Prior Art	41		



			Ogura Does Not Add Anything to the Kaken Abstracts	43	
	C.		Secondary Art Cited by Petitioner Only Discloses the Nail rance of Unrelated Compounds	47	
			JP '639 Only Evaluates the Structurally Unrelated Compound Amorolfine	48	
			Amorolfine Never Became Established as an Effective Treatment for Onychomycosis, Demonstrating Further Unpredictability	51	
			The '367 Patent and Hay Only Evaluate Another Structurally Unrelated Compound, Tioconazole	53	
			The '367 Patent Fails to Offer Any Data Establishing Efficacy for Tioconazole	54	
			Hay Likewise Fails to Establish Efficacy Even for Tioconazole Because of Poor Study Design	55	
	D.	Nail v	Iotivation to Apply the Claimed Triazole Compounds to with a Reasonable Expectation of Successfully Treating homycosis	56	
VIII.	Topical Treatment of Onychomycosis with Other Triazole Antifungal Agents Would Not Have Been Obvious Either				
IX.	Secondary Considerations Support the Nonobviousness of the Invention				
X.	Conc	lusion		65	




TABLE OF AUTHORITIES

	Page(s)
Federal Cases	
Aceto Agricultural Chem. Corp. v. Gowan Co., IPR2016-00076, Paper 51 (Final Written Decision)	48
ACTV, Inc. v. Walt Disney Co., 346 F.3d 1082 (Fed. Cir. 2003)	29
Cooper v. Goldfarb, 154 F.3d 1321 (Fed. Cir. 1998)	41
Crocs Inc. v. International Trade Com'n, 598 F.3d 1294 (Fed. Cir. 2010)	61, 63
Dynamic Drinkware LLC v. Nat'l Graphics, Inc., IPR2013-00131, Paper 42 (Final Written Decision)	42
Hockerson-Halberstadt, Inc. v. Converse Inc., 183 F.3d 1369 (Fed. Cir. 1999)	29
Innopharma Licensing, Inc. v. Senju Pharm. Co., Ltd., IPR2015-00902 (Paper 90, 17)	64
Insite Vision Inc. v. Sandoz, Inc., 783 F.3d 853 (Fed. Cir. 2015)	33, 45, 52, 58
Intelligent Bio-systems Inc. v. Illumina Cambridge LTD, 821 F.3d 1359 (Fed. Cir., May 9, 2016)	47
<i>In re Kahn</i> , 441 F.3d 977 (Fed. Cir. 2006)	41
KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398	46
Loral Fairchild Corp. v. Matsushita Elec. Indus. Co., Ltd., 266 F.3d 1358 (Fed. Cir. 2001)	42
In re Magnum Oil Tools, 829 F.3d 1364 (Fed. Cir. 2016)	32



Mahurkar v. C.R. Bard, Inc., 79 F.3d 1572 (Fed. Cir. 1996)42, 43
Medichem, S.A. v. Rolabo, S.L., 437 F.3d 1157 (Fed. Cir. 2006)
Otsuka Pharm. Co., Ltd. v. Sandoz, Inc., 678 F.3d 1280 (Fed. Cir. 2012)
In re Paulsen, 30 F.3d 1475 (Fed. Cir. 1994)28
Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005) (en banc)
Procter & Gamble Co. v. Teva Pharms. USA, Inc., 566 F.3d 989 (Fed. Cir. 2009) 32
SAS Inst., Inc. v. ComplementSoft, LLC., 825 F.3d 1341 (Fed. Cir. 2016)
Sequenom Inc. v. Stanford, IPR2013-00390, Paper 45 (Final Written Decision) (P.T.A.B. Nov. 25, 2014)
Takeda Chem. Indus. Ltd. v. Alphapharm Pty., Ltd., 492 F.3d 1350 (Fed. Cir. 2007)51
Transocean Offshore Deepwater Drilling, Inc. v. Maersk Contractors USA, Inc., 617 F.3d 1296 (Fed. Cir. 2010)60
W.L. Gore & Assoc., Inc. v. Garlock, Inc., 721 F.2d 1540 (Fed. Cir. 1983)
Federal Statutes
35 U.S.C. § 103(a)
Regulations
37 C.F.R. § 42.100(b)



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

